Intellipharmaceutics International Inc. in an “At-The-Market” offering
Blank Rome represented Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs in an “at-the-market” offering to, from time to time, sell common shares for up to an aggregate of $16.8 million. The transaction closed in November 2013.